MaaT Pharma: Advancing a pipeline of novel microbiome therapies across oncology
Cure51 – A unique Xenium dataset of cancer outliers
Regorafenib plus avelumab in advanced neuroendocrine tumors — and the IDO1 biomarker that predicts resistance
Why do gastric cancers resist PD-1 plus antiangiogenesis? Spatial and plasma profiling points to M2 macrophages
Can a single gut bacterium rescue failing immunotherapy? F. prausnitzii strain EXL01 restores checkpoint-inhibitor response
How to screen for mature tertiary lymphoid structures in routine pathology — a standardized method validated across 357 tumors
Can a simple blood test predict who responds to immunotherapy? Circulating L-arginine tracks checkpoint-inhibitor survival
Does acetaminophen blunt cancer immunotherapy? Plasma evidence links paracetamol to worse checkpoint-inhibitor outcomes
Low plasma Arginine level is associated with resistance to immune checkpoint inhibitors in patients with advanced cancer
Background In the era of immuno-oncology, identifying primary resistance mechanisms to immune checkpoint inhibitors remains crucial. A better understanding of these mechanisms may help to identify novel pathways that can be targeted to improve response rates, as well as biomarkers that could support the selection of patients more likely to benefit from cancer immunotherapies. Among […]
Why IDO1 inhibitors fell short in cancer immunotherapy — and what comes next for tryptophan targeting
